Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 8/20 | 0.64 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.57 |
| ▸ | PTPRB | P23467 | 1/20 | 0.54 |
| ▸ | CDC25A | P30304 | 1/20 | 0.54 |
| ▸ | CDC25B | P30305 | 1/20 | 0.54 |
| ▸ | PTEN | P60484 | 1/20 | 0.54 |
| ▸ | PTPMT1 | Q8WUK0 | 1/20 | 0.54 |
| ▸ | UNG | P13051 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | PPARD | Q03181 | 1/20 | 0.46 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.45 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.45 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30688506 | 0.90 | SMN1; SMN2 (0.59) | FFAR1KEAP1PTPRBCDC25ACDC25B | |
| SCHEMBL7103281 | 0.90 | SMN1; SMN2 (0.59) | FFAR1KEAP1PTPRBCDC25ACDC25B | |
| SCHEMBL3627230 | 0.84 | KEAP1 (0.60) | FFAR1KEAP1PTPRBCDC25ACDC25B | |
| SCHEMBL20725124 | 0.84 | KEAP1 (0.55) | FFAR1KEAP1PTPRBCDC25ACDC25B | |
| SCHEMBL13538087 | 0.84 | FFAR1 (0.48) | FFAR1KEAP1PTPRBCDC25ACDC25B | |
| SCHEMBL70271 | 0.82 | KEAP1 (0.74) | FFAR1KEAP1PTPRBCDC25ACDC25B | |
| SCHEMBL12646438 | 0.82 | FFAR1 (0.65) | FFAR1KEAP1TRIM24TRIM33FFAR4 | |
| SCHEMBL2388359 | 0.81 | AKR1B1 (0.54) | FFAR1UNGMAOAMAOBPPARD | |
| SCHEMBL9633674 | 0.81 | KEAP1 (0.52) | FFAR1KEAP1PTPRBCDC25ACDC25B | |
| SCHEMBL5020713 | 0.81 | MAOA (0.56) | FFAR1UNGMAOAMAOBTRIM24 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12024531-B2 | Immunoproteasome inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-12024531-B2 | Immunoproteasome inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-12024531-B2 | Immunoproteasome inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2024-07-02 | — | — | US | disclosed |
| CN-111491939-B | Immunoproteasome inhibitors | 普林斯匹亚生物制药公司 | 2023-12-26 | — | — | CN | disclosed |
| US-20230133165-A1 | IMMUNOPROTEASOME INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230133165-A1 | IMMUNOPROTEASOME INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230133165-A1 | IMMUNOPROTEASOME INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2023-05-04 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| EP-3710457-B1 | IMMUNOPROTEASOME INHIBITORS | PRINCIPIA BIOPHARMA INC (US) | 2022-08-03 | — | — | EP | disclosed |
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-24 | — | — | US | disclosed |
| US-20130281324-A1 | BI-FUNCTINAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2013-10-24 | — | — | US | disclosed |
| EP-2558577-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2013-02-20 | — | — | EP | disclosed |
| WO-2011127933-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2011-10-20 | — | — | WO | disclosed |
| US-4175202-A | 4,5,6-Trinor-3,7,-inter-m-phenylene prostaglandin A1 analogs | THE UPJOHN COMPANY (US) | 1979-11-20 | — | — | US | disclosed |
| US-4084058-A | HYPOTENSIVES, ANTICOAGULANTS | THE UPJOHN COMPANY (US) | 1978-04-11 | — | — | US | disclosed |
| US-4053485-A | OPTICALLY ACTIVE OR RACEMIC MIXTURES | THE UPJOHN COMPANY (US) | 1977-10-11 | — | — | US | disclosed |
| US-4032560-A | OXA PHENYLENE PROSTAGLANDIN ANALOGS | THE UPJOHN COMPANY (US) | 1977-06-28 | — | — | US | disclosed |
| US-4020097-A | HYPOTENSIVE, ANTICOAGULANT | THE UPJOHN COMPANY (US) | 1977-04-26 | — | — | US | disclosed |
| US-3997566-A | Tricyclic prostaglandin | THE UPJOHN COMPANY (US) | 1976-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | LRRK2, MYLK2, MYLK | FFAR1 4060/4885KEAP1 955/4885PTPRB 685/4885 |
| US-12024531-B2 | Immunoproteasome inhibitors | PSMC2, PSMB7, PSMB2 | FFAR1 4739/4885KEAP1 1152/4885PTPRB 1938/4885 |
| US-20230133165-A1 | IMMUNOPROTEASOME INHIBITORS | PSMC2, PSMB7, PSMB2 | FFAR1 4739/4885KEAP1 1152/4885PTPRB 1938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.